KLTO
Klotho Neurosciences, Inc.0.3900
+0.0105+2.77%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
28.29MP/E (TTM)
-Basic EPS (TTM)
-0.30Dividend Yield
0%Recent Filings
10-K
8-K
Name change to GRML effective
Greenland Mines Ltd, formerly Klotho Neurosciences, completed its name change via merger effective 5:00 PM March 11, 2026, with common stock switching to GRML ticker on Nasdaq at market open March 12. The rebrand aligns with its recent acquisition of an 80% interest in the Skaergaard Project, boasting 25.4 Moz PdEq indicated and inferred resources. No shareholder action needed. Forward-looking statements highlight execution risks.
8-K
Acquisition closed, GRML launches
Greenland Mines Ltd completed its acquisition of Greenland Mines on March 4, 2026, via convertible preferred equity pending shareholder approval, gaining 80% of the Skaergaard project with 13.2 Moz AuEq resources valued at $68 billion in-situ at Feb 2026 prices. The name change to GRML took effect today, adding a natural resources division to cell and gene therapy while retaining key management. New drilling targets doubling to ~50 million ounces Au, Pd, Pt. Forward-looking plans carry exploration risks.
8-K
Acquires Skaergaard mining project
Klotho Neurosciences completed its merger with Greenland Mines on March 4, 2026, acquiring an 80% interest in Major Precious Greenland A/S and its Skaergaard Project in Greenland—holding 364 million tons at 2.17 g/t PdEq per 2022 NI 43-101—for 47,000 shares of new Series C Preferred Stock, convertible into common post-shareholder approval. Greenland stockholders gain one board seat. Resources unverified; financials pending.
AIBT
Aibotics Inc.
0.00+0.00
ALZN
Alzamend Neuro, Inc.
2.16+0.05
ANRO
Alto Neuroscience, Inc.
17.10+0.07
ANVS
Annovis Bio, Inc.
3.93+0.15
ATHA
Athira Pharma, Inc.
3.88+0.03
IMA
ImageneBio, Inc.
6.25+0.08
KALA
KALA BIO, Inc.
0.56-0.05
KLRS
Kalaris Therapeutics, Inc.
8.66+0.16
KTTA
Pasithea Therapeutics Corp.
1.14-0.02
NGNE
Neurogene Inc.
19.53-0.73